This clinical trial compares feasibility and effectiveness of the open door telehealth intervention to usual care for depressed older adult patients with cancer. Open door for cancer is an intervention with the goal to improve initiation of mental health treatment by providing education regarding depression, identifying treatment preferences, goals, and barriers and referring patients to care. Depression in cancer patients is associated with greater fatigue, nausea, pain, and dyspnea and poor quality of life. Depression is also associated with longer hospitalizations; increased risk of emergency department visits, overnight hospitalization, and 30-day readmission and shorter survival. Successful treatment of depression has the potential to improve older adults with cancer quality of life, cancer care, and morbidity and mortality.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT06037954.
Locations matching your search criteria
United States
New York
New York
NYP/Weill Cornell Medical CenterStatus: Approved
Contact: Jo Anne Sirey
Memorial Sloan Kettering Cancer CenterStatus: Active
Contact: Kelly M McConnell
Phone: 646-888-0026
PRIMARY OBJECTIVES:
I. To evaluate the feasibility, acceptability, and preliminary efficacy of Open Door for Cancer (OD-C) in older adults with cancer (OACs).
II. To identify individual, clinic, and institution-level factors influencing OD-C telehealth implementation and implementation strategies from the perspectives of OACs and medical and psychosocial oncology providers.
OUTLINE: Patients are randomized to 1 of 2 arms. Providers are assigned to arm 3.
ARM I: Patients attend 3 30-minute sessions over 4 weeks followed by a booster call 2 weeks later. Sessions are led by a social worker, where patients receive education about depression and treatment options, discuss treatment preferences, goals and barriers and receive a referral for appropriate services. After completion of study intervention, patients are followed up after the booster call, 6 weeks after the booster call, and may complete an interview after the last follow up.
ARM II: Patients receive usual care consisting of a referral to the appropriate services from the oncology team. After completion of study intervention, patients are followed up at 6 weeks and 12 weeks post randomization.
ARM III: Providers complete an interview on study.
Trial PhaseNo phase specified
Trial Typesupportive care
Lead OrganizationMemorial Sloan Kettering Cancer Center
Principal InvestigatorKelly M McConnell
